Big payer strategics like CVS, United, and Humana are meaningfully constrained on large acquisitions over the next few years. Near-term exit paths for healthtech founders are more likely to be non-payer corporate strategics or PE, and sponsor-led instead of payer-led.

Health plans are buying AI faster than almost any other buyer segment — claims ops, prior auth, utilization management, out-of-network pricing. The bar is moving from "we use AI" to "we integrate cleanly into existing plan workflows."

Corporate and payer buyers still want payer-agnostic positioning. Locking into a single payer too early limits your market and your exit options. One corporate venture arm put it plainly: stay open until the economics force a choice.